Evaluating Bis‐Phenacyl Bromide‐Based Bis‐Heterocyclic Templates as Anticancer Prototypes and Potential PARP1 Inhibitors
ChemMedChem · 2025
DOI: 10.1002/cmdc.202500045 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2025. Verfasst von Refaie M Kassab und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Poly (ADP-Ribose) Polymerase-1, Poly(ADP-ribose) Polymerase Inhibitors, Heterocyclic Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: The Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU).
Abstract (Originalsprache)
Poly(ADP‐ribose) polymerase 1 (PARP1) plays a pivotal role in DNA damage repair and represents a promising antineoplastic target. Novel bis‐heterocyclic derivatives based on a bis‐phenacyl bromide scaffold were synthesized and assessed for their antineoplastic potential against eight malignant cell lines, and PARP1 inhibitory activity. These derivatives exhibited selective cytotoxicity toward MCF7 and PC‐3 cancer cell lines, while showing limited or no toxicity to other malignant cell lines. Derivatives 5a – e , 13 , 18 , 34 , 35 , and 36 (IC 50 < 10 μM) were most effective against PC‐3 cells. Derivatives 5a , 5d , 5e , 12 , 25 , 28a and 34 demonstrated remarkable potency against MCF7 cells (IC 50 = 0.006–0.417 μM), surpassing the efficacy of doxorubicin. Mechanistic investigations indicated that their cytotoxicity involved programmed cell death induction, as evidenced by increased protein expression of caspase‐7, cytochrome C, BAX, and p53, as well as reduced BCL‐2 protein levels, along with sub‐G1 cell cycle cessation via cyclin‐dependent kinase genes expression downregulation. All derivatives showed PARP1 inhibitory activity, with 5a – e , 8a , 13 , 34 , and 36 , outperforming olaparib with sub‐nanomolar IC 50 values. Molecular docking revealed that the derivatives docked well with PARP1, consistent with enzymatic inhibition data. Our findings support further optimization of these bis‐heterocyclic scaffolds as next‐generation anticancer agents and potent PARP1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Faculty of Science, Cairo University, Giza, 12613, Egypt.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
- Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 11623, Saudi Arabia.
- Pharmaceutical Chemistry Department, Egyptian Drug Authority (EDA), Giza, 12311, Egypt.
- Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt.
ORCID-Profile: Mohamed A M Ali
Förderung
- The Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)
Zitieren
APA
Kassab, R. M., Ali, M. A. M., Al-Hussain, S. A., Zaki, M. E. A., Muhammad, Z. A., & Abdel Halim, A. S. (2025). Evaluating Bis‐Phenacyl Bromide‐Based Bis‐Heterocyclic Templates as Anticancer Prototypes and Potential PARP1 Inhibitors. ChemMedChem. https://doi.org/10.1002/cmdc.202500045
Vancouver
Kassab RM, Ali MAM, Al-Hussain SA, Zaki MEA, Muhammad ZA, Abdel Halim AS. Evaluating Bis‐Phenacyl Bromide‐Based Bis‐Heterocyclic Templates as Anticancer Prototypes and Potential PARP1 Inhibitors. ChemMedChem. 2025. doi:10.1002/cmdc.202500045
BibTeX
@article{Kassab2025,
author = {Kassab, Refaie M and Ali, Mohamed A M and Al-Hussain, Sami A and Zaki, Magdi E A and Muhammad, Zeinab A and Abdel Halim, Alyaa S},
title = {Evaluating Bis‐Phenacyl Bromide‐Based Bis‐Heterocyclic Templates as Anticancer Prototypes and Potential PARP1 Inhibitors},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202500045}
}
EUVIMED